重大事件
即時報告
8-K
2026-07-20
Tenon Medical 獲納斯達克確認恢復股東權益合規，惟警告未來仍有除牌風險
AI 繁中摘要
申報類型：8-K（新聞稿）
Tenon Medical, Inc.（納斯達克代碼：TNON）於2026年7月20日發佈公告，表示已接獲納斯達克通知，成功恢復符合持續上市所要求的股東權益最低門檻（250萬美元）。💪
這次合規主要得益於公司在2026年7月1日完成的合共420萬美元普通股及認股權證公開發售。公司在7月10日提交的8-K中已表明相信能符合納斯達克上市規則5550(b)(1)，並於7月17日正式獲得確認恢復合規。
不過，公司亦提醒投資者，若在提交2026年9月30日止季度報告（10-Q）時未能再次證明符合股東權益要求，仍可能面臨除牌風險，屆時將可提出上訴。⚠️
Tenon Medical 是一家專注於治療骶骨盆腔疾病的醫療器械公司，目前提供兩套系統治療骶髂關節病變：Catamaran™ SI Joint Fusion System（採用單一鈦合金植入物，微創方式）及在2025年8月收購所得的 SImmetry+® SI Joint Fusion System（側向微創解決方案）。公司自2022年10月全國推出Catamaran系統後，主要聚焦三個商用方向：原發性骶髂關節手術、失敗植入物的翻修手術，以及作為脊柱融合手術的輔助治療。
展望方面，管理層強調會繼續努力維持納斯達克的上市資格，但同時提醒未來業績報告中的合規表現仍屬關鍵。投資者應留意公司能否在下一份10-Q中持續展現足夠的股東權益，否則將面臨除牌風險，對股價及流通性造成潛在負面影響。
更多資料可參閱公司網站 www.tenonmed.com，以及SEC存檔文件（包括2025年度10-K及後續10-Q）中的風險因素章節。
展開英文正文
EX-99.1 2 ea029843101ex99-1.htm PRESS RELEASE OF TENON MEDICAL, INC., DATED JULY 20, 2026 Exhibit 99.1 Tenon Medical, Inc. Announces Regained Compliance with Nasdaq Stockholders’ Equity Requirement LOS GATOS, CA / ACCESS Newswire / July 20, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from Nasdaq that the Company regained compliance with the continued listing requirement relating to maintaining a minimum of $2.5 million in stockholders’ equity. On July 17, 2026, the Company received a notice from Nasdaq that, based on the July 10 8-K (as defined below), the Company had regained compliance with the Stockholders’ Equity Rule (as defined below). However, if the Company fails to evidence compliance upon filing its Quarterly Report on Form 10-Q for the period ending September 30, 2026, the Company may be subject to delisting, and any such delisting would be subject to appeal. On July 10, 2026, the Company filed a Current Report on Form 8-K (the “July 10 8-K”) that disclosed its belief that it satisfied Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”) as of such filing date due to the completion of its $4.2 million public offering of common stock and warrants on July 1, 2026. About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the “SI Joint”). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct. For more information, please visit www.tenonmed.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release. The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “projects,” “plans,” “expects,” “seek,” “believes,” “see,” “should,” “will,” “would,” “target,” and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, including the Stockholders’ Equity Rule, and the risk that the Company’s common stock may be delisted from Nasdaq if the Company fails to evidence such compliance in its future periodic reports. Such statements are based on Tenon’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon’s actual results to be materially different than those expressed in any forward-looking statements, please review Tenon’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated from time to time in our Form 10-Q filings and our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled “Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law. Investor Contact Shannon Devine MZ North America 203-741-8811 [email protected]